Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Dam

Showing results (111-120 of 135) with videos related to

Pageof 14
Sort By:
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 28, 2021
Pretreatment qEEG biomarkers for predicting pharmacological treatment outcome in major depressive disorder: Independent validation from the NeuroPharm studyCheng-Teng Ip, Sebastian Olbrich, Melanie Ganz, et al.
Journal of Psychiatric Research|June 27, 2021
NeuroPharm study: EEG wakefulness regulation as a biomarker in MDDCheng-Teng Ip, Melanie Ganz, Vibeke H Dam, et al.
Inorganic Chemistry|February 28, 2006
A novel heteroditopic terpyridine-pincer ligand as building block for mono- and heterometallic Pd(II) and Ru(II) complexesMarcella Gagliardo, Gema Rodríguez, Henk H Dam, et al.
Biochemistry|October 28, 1998
Dimerization of native myosin LC2(RLC)-free subfragment 1 from adult rabbit skeletal muscleJ E Morel, K Taouil, N D'hahan, et al.
Biological Psychiatry|August 24, 2024
Effect of Antidepressant Treatment on 5-HT<sub>4</sub> Receptor Binding and Associations With Clinical Outcomes and Verbal Memory in Major Depressive DisorderVibeke H Dam, Kristin Köhler-Forsberg, Brice Ozenne, et al.
Neuroscience Applied|July 14, 2025
The BrainDrugs-epilepsy study: A prospective open-label cohort precision medicine study in epilepsyMaja R Marstrand-Joergensen, Vibeke H Dam, Kirsten Vinter, et al.
Translational Psychiatry|July 12, 2022
Concurrent anxiety in patients with major depression and cerebral serotonin 4 receptor binding. A NeuroPharm-1 studyKristin Köhler-Forsberg, Brice Ozenne, Søren V Larsen, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 15, 2025
Amygdala reactivity to threat, negative facial perception, and risk of future psychiatric hospitalizations: a longitudinal study in major depressive and bipolar disordersKamilla W Miskowiak, Brice Ozenne, Hanne L Kjærstad, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 2, 2026
Correction: Amygdala reactivity to threat, negative facial perception, and risk of future psychiatric hospitalizations: a longitudinal study in major depressive and bipolar disordersKamilla W Miskowiak, Brice Ozenne, Hanne L Kjærstad, et al.
Frontiers in Psychiatry|August 15, 2020
Predicting Treatment Outcome in Major Depressive Disorder Using Serotonin 4 Receptor PET Brain Imaging, Functional MRI, Cognitive-, EEG-Based, and Peripheral Biomarkers: A NeuroPharm Open Label Clinical Trial ProtocolKristin Köhler-Forsberg, Anders Jorgensen, Vibeke H Dam, et al.
Pageof 14

Showing results (111-120 of 135) with videos related to

Sort By:
Pageof 14
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 28, 2021
Pretreatment qEEG biomarkers for predicting pharmacological treatment outcome in major depressive disorder: Independent validation from the NeuroPharm studyCheng-Teng Ip, Sebastian Olbrich, Melanie Ganz, et al.
Journal of Psychiatric Research|June 27, 2021
NeuroPharm study: EEG wakefulness regulation as a biomarker in MDDCheng-Teng Ip, Melanie Ganz, Vibeke H Dam, et al.
Inorganic Chemistry|February 28, 2006
A novel heteroditopic terpyridine-pincer ligand as building block for mono- and heterometallic Pd(II) and Ru(II) complexesMarcella Gagliardo, Gema Rodríguez, Henk H Dam, et al.
Biochemistry|October 28, 1998
Dimerization of native myosin LC2(RLC)-free subfragment 1 from adult rabbit skeletal muscleJ E Morel, K Taouil, N D'hahan, et al.
Biological Psychiatry|August 24, 2024
Effect of Antidepressant Treatment on 5-HT<sub>4</sub> Receptor Binding and Associations With Clinical Outcomes and Verbal Memory in Major Depressive DisorderVibeke H Dam, Kristin Köhler-Forsberg, Brice Ozenne, et al.
Neuroscience Applied|July 14, 2025
The BrainDrugs-epilepsy study: A prospective open-label cohort precision medicine study in epilepsyMaja R Marstrand-Joergensen, Vibeke H Dam, Kirsten Vinter, et al.
Translational Psychiatry|July 12, 2022
Concurrent anxiety in patients with major depression and cerebral serotonin 4 receptor binding. A NeuroPharm-1 studyKristin Köhler-Forsberg, Brice Ozenne, Søren V Larsen, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 15, 2025
Amygdala reactivity to threat, negative facial perception, and risk of future psychiatric hospitalizations: a longitudinal study in major depressive and bipolar disordersKamilla W Miskowiak, Brice Ozenne, Hanne L Kjærstad, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 2, 2026
Correction: Amygdala reactivity to threat, negative facial perception, and risk of future psychiatric hospitalizations: a longitudinal study in major depressive and bipolar disordersKamilla W Miskowiak, Brice Ozenne, Hanne L Kjærstad, et al.
Frontiers in Psychiatry|August 15, 2020
Predicting Treatment Outcome in Major Depressive Disorder Using Serotonin 4 Receptor PET Brain Imaging, Functional MRI, Cognitive-, EEG-Based, and Peripheral Biomarkers: A NeuroPharm Open Label Clinical Trial ProtocolKristin Köhler-Forsberg, Anders Jorgensen, Vibeke H Dam, et al.
Pageof 14